Pka Riiβ Protein (Protein Kinase A Regulatory Subunit 2B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | PKA RIIβ (Protein Kinase cAMP-Dependent Regulatory Subunit Type II Beta) |
|---|
| Gene | PRKAR2B |
|---|
| UniProt ID | P31321 |
|---|
| PDB ID | 1R2A, 2Q0J, 4DG0 |
|---|
| Molecular Weight | 45.5 kDa |
|---|
| Subcellular Localization | Cytoplasm, Synapse, Nucleus |
|---|
| Protein Family | cAMP-Dependent Protein Kinase Regulatory Subunit Family |
|---|
PKA RIIβ is the neuron-specific regulatory subunit of protein kinase A (PKA). The RIIβ-containing PKA is particularly important in the brain, where it regulates synaptic plasticity, memory formation, and tau phosphorylation.
PRKAR2B is a 404-amino acid regulatory subunit:
- Dimerization/docking (D/D) domain
- Two cAMP-binding domains (A and B)
- Phosphorylation site at Ser114
- PKA activation: Binds and inhibits catalytic subunits until cAMP binding[1]
- Synaptic plasticity: Essential for LTP and LTD in hippocampus
- Gene transcription: Activates CREB-mediated transcription
- Tau phosphorylation: PKA phosphorylates tau at Ser214, Ser262, Ser409[2]
- Memory formation: cAMP/PKA/CREB pathway critical for learning
- Dopamine signaling: Modulates dopaminergic neurotransmission
- Neuroprotection: Regulates neuronal survival pathways
- Altered PKA activity in AD brains
- RIIβ expression changes in AD
- Tau hyperphosphorylation by dysregulated PKA
- Therapeutic targeting of cAMP/PKA pathway
- PKA phosphorylates pathogenic tau sites
- 4R-tauopathies show altered PKA regulation
- PRKAR2B polymorphisms in bipolar disorder
- Antidepressant response involvement
- Brandon EP, et al. (1998). PKA and neuronal function. Learn Mem. PMID:9735903
- Liu F, et al. (2006). PKA phosphorylates tau. J Neurochem. PMID:16417578
- Bergkvist L, et al. (2016). PRKAR2B in psychiatric disorders. Transl Psychiatry. PMID:27404285
Research on PKA RIIβ in neurodegeneration focuses on understanding its role in tau phosphorylation and synaptic plasticity. Studies have shown that RIIβ-containing PKA holoenzymes are particularly important for memory consolidation, making them attractive targets for AD therapeutics[6]. Selective RIIβ modulators are being developed to enhance PKA activity in neurons while minimizing peripheral side effects.
The connection between RIIβ dysfunction and circadian rhythm disturbances in neurodegenerative diseases is an emerging research area. Given the role of PKA in circadian clock gene expression, RIIβ may provide a mechanistic link between circadian disruption and neurodegeneration[7].
- Bollen M et al. (2014). Targeting PKA in tauopathies. Cell Signal. PMID:24859609
- Luo Y et al. (2021). PKA and circadian rhythm in Alzheimer's disease. J Neurosci. PMID:33853891
The study of Pka Riiβ Protein (Protein Kinase A Regulatory Subunit 2B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Turner MR, et al. "Protein kinase A subunits in neurodegeneration." J Neurochem. 2020;155(2):145-158. PMID:32187890
- Kim H, et al. "PKA RIIβ in tau phosphorylation and synaptic plasticity." Cell Mol Neurobiol. 2019;39(6):763-776. PMID:31124123
- Liu F, et al. "cAMP/PKA signaling in Alzheimer's disease models." Mol Neurobiol. 2018;55(12):8897-8912. PMID:29627910
- Beraldo FH, et al. "PKA dysfunction in Parkinson's disease." Front Cell Neurosci. 2019;13:305. PMID:31440156
- Zhao W, et al. "PRKAR2B genetic variants and neuropsychiatric disorders." Neurosci Lett. 2017;639:90-96. PMID:28049023
PKA RIIβ is being explored as a therapeutic target:
- PKA modulators: Compounds targeting PKA activity
- Gene therapy: Viral vector approaches
- Protein-protein interaction inhibitors: Targeting RIIβ-specific interactions
- Understanding PKA isoform specificity in neurons
- Developing brain-penetrant PKA modulators
- Biomarker development
RIIβ expression may serve as a biomarker:
- Neuronal activity: PKA signaling marker
- Disease progression: Correlation with cognitive decline
- Therapeutic response: Treatment efficacy
Future research priorities:
- Isoform-specific functions in different neuron types
- Post-translational regulation
- Interaction with other signaling pathways
- Biomarker development
- Therapeutic targeting strategies
- Personalized medicine approaches